Cervix Uteri Carcinoma in Situ malady

Categories: Cancer diseases

Aliases & Classifications for Cervix Uteri Carcinoma in Situ

Aliases & Descriptions for Cervix Uteri Carcinoma in Situ:

Name: Cervix Uteri Carcinoma in Situ 12 14
Carcinoma in Situ of Uterine Cervix 12 69
Cervical Intraepithelial Neoplasia 42 69
Cervical Intraepithelial Neoplasia Grade Iii with Severe Dysplasia 12
Cervix Intraepithelial Neoplasia Grade 3 Ajcc V7 69
Squamous Intraepithelial Neoplasia, Grade Iii 12
Cin Iii - Carcinoma in Situ of Cervix 12
Severe Dysplasia of the Cervix Uteri 12
Cin Iii - Severe Dyskaryosis 12
Carcinoma in Situ of Cervix 12
Carcinoma of Cervix Stage 0 12
Severe Dysplasia of Cervix 12
Cervix Ca in Situ 12
Cin Iii 12


Summaries for Cervix Uteri Carcinoma in Situ

MalaCards based summary : Cervix Uteri Carcinoma in Situ, also known as carcinoma in situ of uterine cervix, is related to louse-borne relapsing fever and clear cell adenofibroma. An important gene associated with Cervix Uteri Carcinoma in Situ is SERPIND1 (Serpin Family D Member 1), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Oncogene Induced Senescence. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, and related phenotype is mortality/aging.

Related Diseases for Cervix Uteri Carcinoma in Situ

Diseases related to Cervix Uteri Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Related Disease Score Top Affiliating Genes
1 louse-borne relapsing fever 10.3 CDKN2A GP6
2 clear cell adenofibroma 10.2 CDKN2A TP53
3 lacrimal gland adenoid cystic carcinoma 10.2 CDKN2A TP53
4 pericardium leiomyoma 10.2 CDKN2A TP53
5 spondylarthropathy 10.2 CDKN2A TP53
6 lacrimal gland squamous cell carcinoma 10.2 CDKN2A TP53
7 endometrial squamous cell carcinoma 10.2 CDKN2A TP53
8 ampulla of vater neoplasm 10.2 CDKN2A TP53
9 coccidiosis 10.2 CDKN2A TP53
10 postpoliomyelitis syndrome 10.2 CDKN2A TP53
11 small intestine leiomyoma 10.2 KRT17 TP53
12 paraphimosis 10.2 CDKN2A TP53
13 anal carcinoma in situ 10.2 CDKN2A TP53
14 oro-mandibular-limb hypogenesis syndrome 10.2 CDKN2A TP53
15 brain stem medulloblastoma 10.2 CDKN2A TP53
16 cecum lymphoma 10.2 CDKN2A GP6 SERPIND1
17 uterine disease 10.2 CDKN2A TP53
18 non-suppurative otitis media 10.2 GP6 TP53
19 barbiturate dependence 10.2 CDKN2A GP6 SERPIND1
20 vulvovaginal candidiasis 10.2 CDKN2A GP6 SERPIND1
21 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A TP53
22 spastic ataxia 5 10.2 CDKN2A TP53
23 gallbladder pleomorphic giant cell adenocarcinoma 10.2 CDKN2A TP53
24 endocervical type cervical mucinous adenocarcinoma 10.2 CDKN2A INSM1
25 adult epithelioid sarcoma 10.2 CDKN2A TP53
26 posterior myocardial infarction 10.2 CDKN2A INSM1
27 cervical verrucous carcinoma 10.1 CDKN2A TP53
28 house allergic alveolitis 10.1 CDKN2A TP53
29 thymus squamous cell carcinoma 10.1 CDKN2A KRT17 TP53
30 mitochondrial encephalomyopathy 10.1 CDKN2A KRT17 TP53
31 breast leiomyoma 10.1 CDKN2A KRT17 TP53
32 acquired hemangioma 10.1 CDKN2A TP53
33 chronic monocytic leukemia 10.1 CDKN2A TP53
34 ovarian mesodermal adenosarcoma 10.1 GP5 GP6
35 cryoglobulinemia 10.0 CDKN2A FHIT TP53
36 urethral verrucous carcinoma 10.0 CDKN2A TP53
37 spinal muscular atrophy with progressive myoclonic epilepsy 10.0 CDKN2A FHIT TP53
38 facial dermatosis 10.0 CDKN2A FHIT TP53
39 hepatic flexure cancer 10.0 CDKN2A FHIT TP53
40 non-distal monosomy 10q 10.0 CDKN2A FHIT TP53
41 bladder colloid adenocarcinoma 10.0 INSM1 TP53
42 thanatophoric dysplasia, type ii 10.0 CDKN2A FHIT TP53
43 pyomyositis 10.0 CDKN2A KRT17 SERPIND1 TP53
44 hypogonadotropic hypogonadism 20 with or without anosmia 10.0 CDKN2A FHIT TP53
45 acute inflammation of lacrimal passage 10.0 GP5 GP6 KRT17
46 striated muscle rhabdoid tumor 9.9 CDKN2A GP5
47 vaginal adenosarcoma 9.9 GP5 GP6 TP53
48 cervicitis 9.9
49 pityriasis rosea 9.8 CDKN2A GP5 GP6 TP53
50 vulvar alveolar soft part sarcoma 9.8 CDKN2A GP5

Comorbidity relations with Cervix Uteri Carcinoma in Situ via Phenotypic Disease Network (PDN):

Endometriosis of Uterus Uterine Fibroid

Graphical network of the top 20 diseases related to Cervix Uteri Carcinoma in Situ:

Diseases related to Cervix Uteri Carcinoma in Situ

Symptoms & Phenotypes for Cervix Uteri Carcinoma in Situ

MGI Mouse Phenotypes related to Cervix Uteri Carcinoma in Situ:

id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.28 CDKN2A COL27A1 FHIT GP6 INSM1 KLHL40

Drugs & Therapeutics for Cervix Uteri Carcinoma in Situ

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006

Drugs for Cervix Uteri Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Aluminum hydroxide Approved Phase 4,Phase 3 21645-51-2
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
3 Monophosphoryl lipid A Phase 4
Menthol Approved Phase 2, Phase 3 2216-51-5 16666
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
Lidocaine Approved, Vet_approved Phase 3,Phase 2 137-58-6 3676
Imiquimod Approved, Investigational Phase 3,Phase 2,Phase 1 99011-02-6 57469
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Fluorouracil Approved Phase 3 51-21-8 3385
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
acetic acid Approved, Nutraceutical Phase 3 64-19-7 176
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
Fenretinide Investigational Phase 3 65646-68-6
15 Retinamide Phase 3
16 pancreatic polypeptide Phase 3
Retinol acetate Phase 3 127-47-9 10245972
18 interferons Phase 3,Phase 2,Phase 1
19 Analgesics Phase 3,Phase 2
20 Adjuvants, Anesthesia Phase 3
21 Adjuvants, Immunologic Phase 3,Phase 1,Phase 2
22 Narcotics Phase 3
23 Sodium Channel Blockers Phase 3,Phase 2
24 Trace Elements Phase 3
25 Analgesics, Opioid Phase 3
26 Anesthetics Phase 3,Phase 2
27 Diuretics, Potassium Sparing Phase 3,Phase 2
28 Anesthetics, General Phase 3
29 Anesthetics, Intravenous Phase 3
30 Peripheral Nervous System Agents Phase 3,Phase 2
31 Anesthetics, Local Phase 3,Phase 2
32 Epinephryl borate Phase 3,Phase 2
33 Pharmaceutical Solutions Phase 3
34 Anti-Arrhythmia Agents Phase 3,Phase 2
35 Immunoglobulins Phase 3,Phase 1
36 Anti-Infective Agents Phase 3,Phase 2,Phase 1
37 Immunosuppressive Agents Phase 3
38 Protective Agents Phase 3,Phase 2
39 Interferon Inducers Phase 3,Phase 2,Phase 1
40 Racepinephrine Phase 3,Phase 2
41 Liver Extracts Phase 3
42 Antimetabolites Phase 3
43 Antimetabolites, Antineoplastic Phase 3
44 Antibodies Phase 3,Phase 1
45 Micronutrients Phase 3
46 Antiviral Agents Phase 3,Phase 2,Phase 1
47 Central Nervous System Depressants Phase 3,Phase 2
48 vitamin d Phase 3
49 Progestins Phase 3,Phase 2
50 Aluminum sulfate Phase 3

Interventional clinical trials:

(show top 50) (show all 156)
id Name Status NCT ID Phase
1 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
2 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
3 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
4 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4
5 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
6 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Not yet recruiting NCT03051516 Phase 4
7 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
8 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
9 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
10 Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit Completed NCT00237562 Phase 3
11 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
12 A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3
13 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
14 Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Completed NCT01014026 Phase 3
15 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) Completed NCT00092534 Phase 3
16 Fenretinide in Treating Patients With Cervical Neoplasia Completed NCT00003075 Phase 3
17 Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study Completed NCT00929526 Phase 3
18 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
20 Lidocaine Spray Compared With Submucosal Injection During LEEP: a Randomized Controlled Trial Completed NCT01505920 Phase 3
21 Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix Recruiting NCT02346227 Phase 3
22 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Recruiting NCT02059499 Phase 3
23 Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer Active, not recruiting NCT01608451 Phase 3
24 Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine Active, not recruiting NCT01735006 Phase 3
25 A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls Active, not recruiting NCT02562508 Phase 3
26 Spectroscopy Versus Standard Care in Cervical Cancer Patients Terminated NCT00529464 Phase 3
27 Imiquimod Treatment of CIN Lesions Terminated NCT02329171 Phase 3
28 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
29 SGN-00101 in Treating Patients With Cervical Intraepithelial Neoplasia Unknown status NCT00060099 Phase 2
30 Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Completed NCT00365716 Phase 2
31 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00121173 Phase 1, Phase 2
32 A Trial for Patients With Advanced/Recurrent Cervical Cancer Completed NCT00190983 Phase 2
33 Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00006079 Phase 2
34 Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix Completed NCT00266084 Phase 1, Phase 2
35 A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL) Completed NCT00596258 Phase 2
36 Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine Completed NCT01356823 Phase 2
37 Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia Completed NCT00303823 Phase 2
38 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Completed NCT00054041 Phase 2
39 Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia Completed NCT00031759 Phase 2
40 Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia Completed NCT01256424 Phase 2
41 SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia Completed NCT00075569 Phase 2
42 A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 Completed NCT01304524 Phase 2
43 Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3) Completed NCT01303328 Phase 2
44 Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix Completed NCT00285207 Phase 2
45 Cold Knife Conization With and Without Lateral Hemostatic Sutures Completed NCT02184975 Phase 2
46 Buffered Lidocaine for Loop Electrosurgical Excision Procedures (LEEPs) Completed NCT01405768 Phase 2
47 How to Avoid Cervical Stenosis After LEEP in High Grade Cervical Dysplasia? Recruiting NCT02500966 Phase 1, Phase 2
48 A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions Recruiting NCT02481414 Phase 2
49 Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) Recruiting NCT02631863 Phase 2
50 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia Active, not recruiting NCT00081263 Phase 2

Search NIH Clinical Center for Cervix Uteri Carcinoma in Situ

Cochrane evidence based reviews: cervical intraepithelial neoplasia

Genetic Tests for Cervix Uteri Carcinoma in Situ

Anatomical Context for Cervix Uteri Carcinoma in Situ

MalaCards organs/tissues related to Cervix Uteri Carcinoma in Situ:


Publications for Cervix Uteri Carcinoma in Situ

Variations for Cervix Uteri Carcinoma in Situ

Expression for Cervix Uteri Carcinoma in Situ

Search GEO for disease gene expression data for Cervix Uteri Carcinoma in Situ.

Pathways for Cervix Uteri Carcinoma in Situ

GO Terms for Cervix Uteri Carcinoma in Situ

Biological processes related to Cervix Uteri Carcinoma in Situ according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.5 GP5 GP6 SERPIND1
2 intrinsic apoptotic signaling pathway by p53 class mediator GO:0072332 9.37 FHIT TP53
3 positive regulation of cell cycle arrest GO:0071158 9.26 INSM1 TP53
4 negative regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032435 9.16 FHIT KLHL40
5 replicative senescence GO:0090399 8.96 CDKN2A TP53
6 hemostasis GO:0007599 8.8 GP5 GP6 SERPIND1

Sources for Cervix Uteri Carcinoma in Situ

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....